64 related articles for article (PubMed ID: 23926573)
1. Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.
Daly EJ; Kent JM; Janssens L; Newcomer JW; Hüsken G; De Boer P; Tritsmans L; Schmidt ME
Ann Clin Psychiatry; 2013 Aug; 25(3):173-83. PubMed ID: 23926573
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effects of olanzapine in patients with newly diagnosed psychosis.
Fernandez-Egea E; Miller B; Garcia-Rizo C; Bernardo M; Kirkpatrick B
J Clin Psychopharmacol; 2011 Apr; 31(2):154-9. PubMed ID: 21346617
[TBL] [Abstract][Full Text] [Related]
3. Metabolic issues in schizophrenic patients receiving antipsychotic treatment.
Gupta A; Dadheech G; Yadav D; Sharma P; Gautam S
Indian J Clin Biochem; 2014 Apr; 29(2):196-201. PubMed ID: 24757302
[TBL] [Abstract][Full Text] [Related]
4. Assessment of lipid response to acute olanzapine administration in healthy adults.
Nahmias A; Stahel P; Dash S
Endocrinol Diabetes Metab; 2020 Apr; 3(2):e00119. PubMed ID: 32318637
[TBL] [Abstract][Full Text] [Related]
5. Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia.
McEvoy JP; Risinger R; Mykhnyak S; Du Y; Liu CC; Stanford AD; Weiden PJ
J Clin Psychiatry; 2017; 78(8):1103-1109. PubMed ID: 28937706
[TBL] [Abstract][Full Text] [Related]
6. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988
[TBL] [Abstract][Full Text] [Related]
7. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
8. Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.
Kantrowitz JT; Epstein ML; Beggel O; Rohrig S; Lehrfeld JM; Revheim N; Lehrfeld NP; Reep J; Parker E; Silipo G; Ahissar M; Javitt DC
Brain; 2016 Dec; 139(Pt 12):3281-3295. PubMed ID: 27913408
[TBL] [Abstract][Full Text] [Related]
9. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.
Landbloom R; Mackle M; Wu X; Kelly L; Snow-Adami L; McIntyre RS; Mathews M; Hundt C
CNS Spectr; 2017 Aug; 22(4):333-341. PubMed ID: 27821210
[TBL] [Abstract][Full Text] [Related]
10. Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.
Sakurai H; Suzuki T; Bies RR; Pollock BG; Mimura M; Kapur S; Uchida H
J Clin Psychiatry; 2016 Oct; 77(10):1381-1390. PubMed ID: 27788310
[TBL] [Abstract][Full Text] [Related]
11. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Kim E; Correll CU; Mao L; Starr HL; Alphs L
CNS Spectr; 2016 Dec; 21(6):466-477. PubMed ID: 27629292
[TBL] [Abstract][Full Text] [Related]
12. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.
Morlán-Coarasa MJ; Arias-Loste MT; Ortiz-García de la Foz V; Martínez-García O; Alonso-Martín C; Crespo J; Romero-Gómez M; Fábrega E; Crespo-Facorro B
Psychopharmacology (Berl); 2016 Dec; 233(23-24):3947-3952. PubMed ID: 27620899
[TBL] [Abstract][Full Text] [Related]
13. Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia.
Nasrallah HA; Newcomer JW; Risinger R; Du Y; Zummo J; Bose A; Stankovic S; Silverman BL; Ehrich EW
J Clin Psychiatry; 2016 Nov; 77(11):1519-1525. PubMed ID: 27574838
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.
Fleischhacker WW; Hobart M; Ouyang J; Forbes A; Pfister S; McQuade RD; Carson WH; Sanchez R; Nyilas M; Weiller E
Int J Neuropsychopharmacol; 2017 Jan; 20(1):11-21. PubMed ID: 27566723
[TBL] [Abstract][Full Text] [Related]
15. Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial.
Kittipeerachon M; Chaichan W
Schizophr Res; 2016 Oct; 176(2-3):231-238. PubMed ID: 27461399
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study.
Kinoshita T; Bai YM; Kim JH; Miyake M; Oshima N
Psychopharmacology (Berl); 2016 Jul; 233(14):2663-74. PubMed ID: 27271087
[TBL] [Abstract][Full Text] [Related]
17. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study.
Gründer G; Heinze M; Cordes J; Mühlbauer B; Juckel G; Schulz C; Rüther E; Timm J;
Lancet Psychiatry; 2016 Aug; 3(8):717-729. PubMed ID: 27265548
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study.
Isitt JJ; Nadipelli VR; Kouassi A; Fava M; Heidbreder C
Schizophr Res; 2016 Jul; 174(1-3):126-131. PubMed ID: 27066860
[TBL] [Abstract][Full Text] [Related]
19. Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison.
Schooler NR; Marder SR; Chengappa KN; Petrides G; Ames D; Wirshing WC; McMeniman M; Baker RW; Parepally H; Umbricht D; Kane JM
J Clin Psychiatry; 2016 May; 77(5):628-34. PubMed ID: 27035871
[TBL] [Abstract][Full Text] [Related]
20. AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study.
Litman RE; Smith MA; Doherty JJ; Cross A; Raines S; Gertsik L; Zukin SR
Schizophr Res; 2016 Apr; 172(1-3):152-7. PubMed ID: 26922656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
